Physician profile
Wonsuck Kim
NPI 1538130166
$2,713.96
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,480 · 2020: $134 · 2021: $99.99.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $2,029.54 | 2019-2020 | |
| Allergan, INC. | $350.76 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $100.00 | 2019 | |
| Mallinckrodt Hospital Products INC. | $99.99 | 2021 | |
| Novartis Pharmaceuticals Corporation | $34.33 | 2019-2020 | |
| Ocular Therapeutix, INC. | $29.08 | 2019 | |
| Sun Pharmaceutical Industries INC. | $22.16 | 2019 | |
| Shire North American Group INC | $17.79 | 2019 | |
| Aerie Pharmaceuticals, INC. | $17.04 | 2019 | |
| Eyevance Pharmaceuticals LLC | $13.27 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wonsuck Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.